PL2554171T3 - Sposób leczenia chorób - Google Patents
Sposób leczenia choróbInfo
- Publication number
- PL2554171T3 PL2554171T3 PL12007361T PL12007361T PL2554171T3 PL 2554171 T3 PL2554171 T3 PL 2554171T3 PL 12007361 T PL12007361 T PL 12007361T PL 12007361 T PL12007361 T PL 12007361T PL 2554171 T3 PL2554171 T3 PL 2554171T3
- Authority
- PL
- Poland
- Prior art keywords
- diseases
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21918509P | 2009-06-22 | 2009-06-22 | |
US31535010P | 2010-03-18 | 2010-03-18 | |
EP12007361.4A EP2554171B1 (en) | 2009-06-22 | 2010-06-22 | Method for treatment of diseases |
EP10792567A EP2326332B1 (en) | 2009-06-22 | 2010-06-22 | Method for treatment of diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2554171T3 true PL2554171T3 (pl) | 2015-03-31 |
Family
ID=43354875
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL12007362T PL2554172T3 (pl) | 2009-06-22 | 2010-06-22 | Sposób leczenia chorób |
PL11009239T PL2425839T3 (pl) | 2009-06-22 | 2010-06-22 | Sposób leczenia chorób |
PL12007365T PL2554174T3 (pl) | 2009-06-22 | 2010-06-22 | Sposób leczenia chorób |
PL10792567T PL2326332T3 (pl) | 2009-06-22 | 2010-06-22 | Sposób do leczenia chorób |
PL12007363T PL2554173T3 (pl) | 2009-06-22 | 2010-06-22 | Sposób leczenia chorób |
PL12007361T PL2554171T3 (pl) | 2009-06-22 | 2010-06-22 | Sposób leczenia chorób |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL12007362T PL2554172T3 (pl) | 2009-06-22 | 2010-06-22 | Sposób leczenia chorób |
PL11009239T PL2425839T3 (pl) | 2009-06-22 | 2010-06-22 | Sposób leczenia chorób |
PL12007365T PL2554174T3 (pl) | 2009-06-22 | 2010-06-22 | Sposób leczenia chorób |
PL10792567T PL2326332T3 (pl) | 2009-06-22 | 2010-06-22 | Sposób do leczenia chorób |
PL12007363T PL2554173T3 (pl) | 2009-06-22 | 2010-06-22 | Sposób leczenia chorób |
Country Status (25)
Country | Link |
---|---|
US (4) | US9233113B2 (pl) |
EP (7) | EP2425839B1 (pl) |
JP (2) | JP5833549B2 (pl) |
KR (1) | KR101877041B1 (pl) |
CN (3) | CN106109475A (pl) |
AU (1) | AU2010264524B2 (pl) |
BR (1) | BRPI1010087A2 (pl) |
CA (2) | CA2781771A1 (pl) |
DE (1) | DE202010017530U1 (pl) |
DK (6) | DK2554173T3 (pl) |
EA (1) | EA027524B1 (pl) |
ES (6) | ES2398322T3 (pl) |
HK (3) | HK1153127A1 (pl) |
HR (1) | HRP20130123T1 (pl) |
HU (1) | HUE028212T2 (pl) |
IL (1) | IL216951A (pl) |
MX (2) | MX2011013777A (pl) |
MY (1) | MY160127A (pl) |
NZ (2) | NZ615941A (pl) |
PL (6) | PL2554172T3 (pl) |
PT (5) | PT2554172E (pl) |
SG (7) | SG2014008163A (pl) |
SI (1) | SI2326332T1 (pl) |
WO (1) | WO2010151530A1 (pl) |
ZA (1) | ZA201109278B (pl) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006004795A2 (en) | 2004-06-25 | 2006-01-12 | The Johns Hopkins University | Angiogenesis inhibitors |
WO2007009087A2 (en) * | 2005-07-12 | 2007-01-18 | Dmi Biosciences, Inc. | Methods and products for treatment of diseases |
EP2445350A4 (en) * | 2009-06-22 | 2012-12-26 | Dmi Acquisition Corp | METHOD AND PRODUCTS FOR THE TREATMENT OF DISEASES |
EA027524B1 (ru) | 2009-06-22 | 2017-08-31 | Ампио Фармасьютикалс, Инк. | Способ ингибирования гиперпроницаемости сосудов при отеке маклы |
CA2846412A1 (en) * | 2011-10-07 | 2013-04-11 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
US9879255B2 (en) * | 2012-10-02 | 2018-01-30 | University Of Newcastle Upon Tyne | Modulation of RNA activity and vascular permeability |
CN104968350A (zh) * | 2012-12-19 | 2015-10-07 | 安皮奥制药股份有限公司 | 疾病的治疗方法 |
JP6057333B2 (ja) * | 2013-02-25 | 2017-01-11 | 国立大学法人浜松医科大学 | 血管透過性亢進抑制作用の評価方法 |
US9880778B2 (en) | 2015-11-09 | 2018-01-30 | Google Inc. | Memory devices and methods |
US11813262B2 (en) | 2017-11-04 | 2023-11-14 | Massachusetts Institute Of Technology | Compositions and methods to increase muscular strength |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
NL241544A (pl) | 1958-07-23 | |||
GB1123770A (en) | 1966-11-15 | 1968-08-14 | Sterling Drug Inc | 2-cyano-3-oxo-steroids |
US4160027A (en) | 1977-12-20 | 1979-07-03 | Sterling Drug Inc. | Steroid cyanoketones and intermediates |
FR2502098A1 (fr) | 1981-03-23 | 1982-09-24 | Huret & Fils | Dispositif perfectionne de fixation d'un derailleur sur une patte de cadre |
US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5714481A (en) | 1983-08-02 | 1998-02-03 | Research Corporation Technologies, Inc. | Derivatives of 5-androsten-17 ones and 5-androstan-17-ones |
US4617299A (en) | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
US4837212A (en) | 1984-11-15 | 1989-06-06 | University Of Miami | Treatment of hemolytic anemia with danazol |
US4975537A (en) | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
EP0244178A3 (en) | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraocular dosage compositions and method of use |
DE3738620A1 (de) | 1987-11-13 | 1989-05-24 | Luderschmidt Christoph | Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie |
US5407926A (en) | 1987-12-29 | 1995-04-18 | Alcon Laboratories, Inc. | Ophthalmic composition |
JP2680614B2 (ja) | 1988-08-01 | 1997-11-19 | 日清製粉株式会社 | ダナゾール組成物 |
US5990099A (en) | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
US5372996A (en) | 1989-03-10 | 1994-12-13 | Endorecherche, Inc. | Method of treatment of androgen-related diseases |
AU5856090A (en) | 1989-07-07 | 1991-02-06 | Endorecherche Inc. | Androgen derivatives for use in the inhibition of sex steroid activity |
US5972922A (en) | 1990-06-11 | 1999-10-26 | Alcon Laboratories, Inc. | Steroids which inhibit angiogenesis |
CA2081205C (en) | 1990-06-11 | 2001-02-27 | John W. Wilks | Steroids which inhibit angiogenesis |
JPH04149132A (ja) | 1990-10-13 | 1992-05-22 | Bairon Boeki Kk | ダナゾール水溶液 |
JPH0735335B2 (ja) | 1991-02-28 | 1995-04-19 | 五十嵐 正雄 | 子宮内膜症の治療薬 |
KR100249555B1 (ko) | 1991-06-18 | 2000-04-01 | 루게쥐농 프랑스와 | 스테로이드를 함유하는 안구용 조성물, 및 녹내장 치료에 이들 조성물을 사용하는 방법 |
ATE232540T1 (de) | 1991-11-22 | 2003-02-15 | Alcon Lab Inc | Angiostatische steroide |
US5679666A (en) | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
US5770592A (en) | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
GB9200210D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
AU674681B2 (en) | 1992-04-21 | 1997-01-09 | Schepens Eye Research Institute, Inc., The | Ocular androgen therapy in Sjogren's syndrome |
ES2068742B1 (es) | 1993-02-11 | 1995-11-16 | Uriach & Cia Sa J | Nuevos derivados de piridinio. |
US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
US6060462A (en) | 1993-10-20 | 2000-05-09 | Dupont Pharmaceuticals Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
US5646136A (en) | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
EP0754046A1 (en) | 1994-04-04 | 1997-01-22 | FREEMAN, William R. | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
WO2002096927A2 (en) | 2001-05-29 | 2002-12-05 | Ribozyme Pharmaceuticals, Incorporated | Ribozyme based treatment of female reproductive diseases |
US5885591A (en) | 1996-07-02 | 1999-03-23 | Johnson & Johnson Consumer Products, Inc. | Personal lubricant compositions |
US5929111A (en) | 1996-12-18 | 1999-07-27 | Alcon Laboratories, Inc. | A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure |
US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
WO1998043647A1 (en) | 1997-03-28 | 1998-10-08 | Massachusetts Institute Of Technology, Inc. | Regulation of amyloid precursor protein (app) expression by estrogenic compounds |
US6011023A (en) | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
EP0939124A3 (en) | 1998-02-24 | 2001-03-21 | Smithkline Beecham Plc | MGBP1 sequences |
US6645954B2 (en) | 1998-04-09 | 2003-11-11 | Multimed Limited | Compositions comprising ethisterone or its derivatives |
GB9807809D0 (en) | 1998-04-09 | 1998-06-10 | Multimed Ltd | Compositions comprising ethisterone or its derivatives |
EP1104302A4 (en) | 1998-07-10 | 2006-08-09 | Retmed Pty Ltd | PROPHYLACTIC TREATMENTS OF BLOOD VESSEL NEOFORMATION IN MACULAR DEGENERATION |
US20040063719A1 (en) | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
EP1022027A1 (en) | 1999-01-22 | 2000-07-26 | Applied Research Systems ARS Holding N.V. | Tumor necrosis factor antagonists and their use in endometriosis |
EP1074634B1 (en) | 1999-07-09 | 2002-10-02 | Institut Pasteur De Lille | Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease |
US6610674B1 (en) | 1999-09-28 | 2003-08-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone analogs |
DE60016271T2 (de) | 1999-10-21 | 2005-12-01 | Alcon Inc. | Medikamentenzuführvorrichtung |
EP1225879A2 (en) | 1999-10-22 | 2002-07-31 | Orbon Corporation | Ophthalmic formulation of dopamine antagonists |
US6562369B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers |
AU2001230864A1 (en) | 2000-01-12 | 2001-07-24 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
GB2345851B (en) | 2000-01-18 | 2004-05-26 | Gavin Paul Vinson | A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour |
US20020055512A1 (en) | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
CA2373237A1 (en) | 2000-03-10 | 2001-09-20 | Insite Vision Incorporated | Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
EP1311269B1 (en) | 2000-08-04 | 2012-02-29 | DMI Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
US20040082557A1 (en) | 2001-01-26 | 2004-04-29 | Wajszczuk Charles Paul | Methods for treating estrogen-dependent disorders |
EP1372664A1 (en) | 2001-03-01 | 2004-01-02 | Hollis-Eden Pharmaceuticals Inc. | Use of certain steroids for treatment of blood cell deficiencies |
GB2375958B (en) | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
US6936599B2 (en) | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
WO2002087543A1 (en) | 2001-05-01 | 2002-11-07 | Biozone Laboratories, Inc. | Sustained release formulations for nifedipine, dextromethorphan, and danazol |
FR2825277B1 (fr) | 2001-05-30 | 2004-10-15 | Oreal | Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd |
US20030232798A1 (en) | 2001-06-12 | 2003-12-18 | Yadon Arad | Adrenal enzyme inhibitors |
US20030050291A1 (en) | 2001-06-12 | 2003-03-13 | Yadon Arad | Adrenal enzyme inhibitors |
WO2003013609A1 (en) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
CA2480809A1 (en) | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
AU2003278744B2 (en) | 2002-08-28 | 2010-07-29 | Harbor Biosciences, Inc. | Therapeutic treatment methods |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
DE60305068T2 (de) | 2002-12-18 | 2007-01-11 | Laboratoires Besins International | Behandlung von mastalgie mit 4-hydroxy-tamoxifen |
WO2004058289A1 (en) | 2002-12-20 | 2004-07-15 | Chakshu Research, Inc. | Ophthalmic formulation for the prevention and treatment of ocular conditions |
MXPA05007266A (es) | 2003-01-02 | 2006-01-17 | Femmepharma Holding Co Inc | Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno. |
CN100342856C (zh) * | 2003-04-10 | 2007-10-17 | 上海医药工业研究院 | 达那唑半固体骨架制剂的组合物 |
GB2400554B (en) | 2003-04-16 | 2007-04-18 | George Margetts | Treatment of angiotensin II-induced cardiovascular disease |
WO2004103406A1 (ja) | 2003-05-26 | 2004-12-02 | Japan Science And Technology Agency | 血小板の減少または増加を伴う疾患の治療用組成物 |
GB0313612D0 (en) | 2003-06-12 | 2003-07-16 | Novartis Ag | Organic compounds |
US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
EP1691795A2 (en) | 2003-12-03 | 2006-08-23 | LifeCycle Pharma A/S | Pharmaceutical compositions comprising danazol |
GB0329667D0 (en) * | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
US20050143362A1 (en) | 2003-12-31 | 2005-06-30 | Mclane Michael W. | Danazol for treatment of hypogonadism in the adult male |
US7442681B2 (en) * | 2004-02-10 | 2008-10-28 | University Of Virginia Patent Foundation | Method of inhibiting vascular permeability |
CA2557724A1 (en) | 2004-02-27 | 2005-10-06 | Centocor, Inc. | Methods and compositions for treating il-13 related pathologies |
AU2005230811A1 (en) | 2004-04-06 | 2005-10-20 | Angiogenetics Sweden Ab | Angiogenesis-affecting compounds and methods of use thereof |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
WO2006004795A2 (en) | 2004-06-25 | 2006-01-12 | The Johns Hopkins University | Angiogenesis inhibitors |
GB2420281A (en) | 2004-11-22 | 2006-05-24 | Stegram Pharmaceuticals Ltd | Topical formulations for use in the treatment or prevention of dermatological conditions |
GB2421183A (en) | 2004-12-17 | 2006-06-21 | Stegram Pharmaceuticals Ltd | Topical formulations for use in the treatment or prevention of skin cancers |
WO2006082588A2 (en) | 2005-02-07 | 2006-08-10 | Pharmalight Inc. | Method and device for ophthalmic administration of active pharmaceutical ingredients |
WO2006091459A2 (en) | 2005-02-24 | 2006-08-31 | Joslin Diabetes Center, Inc. | Compositions and methods for treating vascular permeability |
WO2006094027A2 (en) | 2005-03-02 | 2006-09-08 | Nascent Pharmaceutical, Inc. | Combination therapy for topical application |
WO2007009087A2 (en) * | 2005-07-12 | 2007-01-18 | Dmi Biosciences, Inc. | Methods and products for treatment of diseases |
US8404643B2 (en) * | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
CN101500579A (zh) | 2006-03-20 | 2009-08-05 | 约翰·霍普金斯大学 | 用于抑制impdh异形体1的方法及组成物 |
US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
US8071779B2 (en) * | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
CN101024082A (zh) | 2007-04-06 | 2007-08-29 | 张士东 | 一种全面预防和治疗心脑血管疾病复方药及其应用 |
ES2493641T3 (es) | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
WO2009036108A1 (en) | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Methods and compositions for inhibiting vascular leakage |
WO2009073843A1 (en) | 2007-12-06 | 2009-06-11 | Cytotech Labs, Llc | Inhalable compositions having enhanced bioavailability |
EP2300011A4 (en) | 2008-05-27 | 2012-06-20 | Dmi Life Sciences Inc | METHODS AND THERAPEUTIC COMPOUNDS |
EP2445350A4 (en) | 2009-06-22 | 2012-12-26 | Dmi Acquisition Corp | METHOD AND PRODUCTS FOR THE TREATMENT OF DISEASES |
EA027524B1 (ru) | 2009-06-22 | 2017-08-31 | Ампио Фармасьютикалс, Инк. | Способ ингибирования гиперпроницаемости сосудов при отеке маклы |
CA2846412A1 (en) | 2011-10-07 | 2013-04-11 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
CN104968350A (zh) | 2012-12-19 | 2015-10-07 | 安皮奥制药股份有限公司 | 疾病的治疗方法 |
-
2010
- 2010-06-22 EA EA201200036A patent/EA027524B1/ru not_active IP Right Cessation
- 2010-06-22 PL PL12007362T patent/PL2554172T3/pl unknown
- 2010-06-22 CA CA2781771A patent/CA2781771A1/en not_active Abandoned
- 2010-06-22 AU AU2010264524A patent/AU2010264524B2/en not_active Ceased
- 2010-06-22 EP EP11009239.2A patent/EP2425839B1/en not_active Not-in-force
- 2010-06-22 DK DK12007363.0T patent/DK2554173T3/en active
- 2010-06-22 US US12/820,398 patent/US9233113B2/en not_active Expired - Fee Related
- 2010-06-22 SG SG2014008163A patent/SG2014008163A/en unknown
- 2010-06-22 PT PT120073622T patent/PT2554172E/pt unknown
- 2010-06-22 EP EP10792567A patent/EP2326332B1/en active Active
- 2010-06-22 SG SG2014009799A patent/SG2014009799A/en unknown
- 2010-06-22 ES ES10792567T patent/ES2398322T3/es active Active
- 2010-06-22 ES ES12007365.5T patent/ES2554688T3/es active Active
- 2010-06-22 DK DK12007361.4T patent/DK2554171T3/da active
- 2010-06-22 PT PT120073614T patent/PT2554171E/pt unknown
- 2010-06-22 PL PL11009239T patent/PL2425839T3/pl unknown
- 2010-06-22 ES ES12007363.0T patent/ES2612748T3/es active Active
- 2010-06-22 NZ NZ615941A patent/NZ615941A/en not_active IP Right Cessation
- 2010-06-22 CN CN201610480273.XA patent/CN106109475A/zh active Pending
- 2010-06-22 MX MX2011013777A patent/MX2011013777A/es active IP Right Grant
- 2010-06-22 JP JP2012517645A patent/JP5833549B2/ja not_active Expired - Fee Related
- 2010-06-22 ES ES12007362.2T patent/ES2523068T3/es active Active
- 2010-06-22 KR KR1020127001781A patent/KR101877041B1/ko active IP Right Grant
- 2010-06-22 ES ES12007361.4T patent/ES2523821T3/es active Active
- 2010-06-22 CA CA2751002A patent/CA2751002C/en not_active Expired - Fee Related
- 2010-06-22 PT PT110092392T patent/PT2425839E/pt unknown
- 2010-06-22 PL PL12007365T patent/PL2554174T3/pl unknown
- 2010-06-22 PL PL10792567T patent/PL2326332T3/pl unknown
- 2010-06-22 PT PT120073655T patent/PT2554174E/pt unknown
- 2010-06-22 DK DK12007362.2T patent/DK2554172T3/da active
- 2010-06-22 MY MYPI2011006154A patent/MY160127A/en unknown
- 2010-06-22 EP EP12007362.2A patent/EP2554172B1/en not_active Not-in-force
- 2010-06-22 BR BRPI1010087A patent/BRPI1010087A2/pt not_active IP Right Cessation
- 2010-06-22 EP EP12007360A patent/EP2554170A1/en not_active Withdrawn
- 2010-06-22 PL PL12007363T patent/PL2554173T3/pl unknown
- 2010-06-22 EP EP12007361.4A patent/EP2554171B1/en not_active Not-in-force
- 2010-06-22 PL PL12007361T patent/PL2554171T3/pl unknown
- 2010-06-22 HU HUE12007365A patent/HUE028212T2/en unknown
- 2010-06-22 DK DK12007365.5T patent/DK2554174T3/da active
- 2010-06-22 EP EP12007365.5A patent/EP2554174B1/en not_active Not-in-force
- 2010-06-22 DE DE202010017530U patent/DE202010017530U1/de not_active Expired - Lifetime
- 2010-06-22 MX MX2014006692A patent/MX336436B/es unknown
- 2010-06-22 NZ NZ597030A patent/NZ597030A/xx not_active IP Right Cessation
- 2010-06-22 CN CN2010800372358A patent/CN102481304A/zh active Pending
- 2010-06-22 EP EP12007363.0A patent/EP2554173B1/en active Active
- 2010-06-22 SG SG2014008171A patent/SG2014008171A/en unknown
- 2010-06-22 CN CN201610971162.9A patent/CN107050036A/zh active Pending
- 2010-06-22 SG SG2014009781A patent/SG2014009781A/en unknown
- 2010-06-22 DK DK10792567.9T patent/DK2326332T3/da active
- 2010-06-22 SG SG2014008155A patent/SG2014008155A/en unknown
- 2010-06-22 SI SI201030136T patent/SI2326332T1/sl unknown
- 2010-06-22 PT PT107925679T patent/PT2326332E/pt unknown
- 2010-06-22 SG SG2014009807A patent/SG2014009807A/en unknown
- 2010-06-22 ES ES11009239.2T patent/ES2523769T3/es active Active
- 2010-06-22 DK DK11009239.2T patent/DK2425839T3/en active
- 2010-06-22 WO PCT/US2010/039458 patent/WO2010151530A1/en active Application Filing
- 2010-06-22 SG SG2011094620A patent/SG176939A1/en unknown
-
2011
- 2011-07-11 HK HK11107136.7A patent/HK1153127A1/xx not_active IP Right Cessation
- 2011-10-19 US US13/276,810 patent/US8227457B2/en not_active Expired - Fee Related
- 2011-12-01 US US13/308,754 patent/US20120077789A1/en not_active Abandoned
- 2011-12-13 IL IL216951A patent/IL216951A/en not_active IP Right Cessation
- 2011-12-15 ZA ZA2011/09278A patent/ZA201109278B/en unknown
-
2013
- 2013-02-12 HR HRP20130123AT patent/HRP20130123T1/hr unknown
- 2013-03-18 HK HK13103306.8A patent/HK1176003A1/xx not_active IP Right Cessation
- 2013-03-27 HK HK13103875.9A patent/HK1176870A1/zh not_active IP Right Cessation
-
2015
- 2015-08-06 JP JP2015155819A patent/JP2015214575A/ja not_active Withdrawn
- 2015-12-02 US US14/956,760 patent/US9987292B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1217763A1 (zh) | 用於治療疾病的方法 | |
HK1169804A1 (zh) | 治療疼痛的方法 | |
HK1176870A1 (zh) | 疾病的治療方法 | |
PT2429524T (pt) | Formulação de ac220 seca por atomização | |
EP2350641A4 (en) | Methods of Treatment | |
EP2544686A4 (en) | COMBINED METHODS FOR THE TREATMENT OF DISEASES | |
EP2416803A4 (en) | NEW METHODS OF TREATING INFLAMMATORY DISEASES | |
PL2281457T3 (pl) | Sposób fizycznego działania na rośliny | |
EP2424539A4 (en) | PROCESS FOR TREATING DEPRESSION | |
EP2585103A4 (en) | METHOD OF TREATMENT | |
EP2440238A4 (en) | Methods of Treatment | |
GB0909807D0 (en) | Method of treatment | |
GB0904164D0 (en) | Method of treatment | |
GB0921823D0 (en) | Method of treatment | |
AU2009903360A0 (en) | Method of Treatment | |
EP2532254A4 (en) | METHOD FOR PROCESSING A LACTO-N BIOSE-CONTAINED SOLUTION | |
GB0823435D0 (en) | Method of treatment | |
GB201000318D0 (en) | Method of treatment |